ClinicalTrials.gg
CompletedNCT00448136Updated Jan 22, 2015Results posted

A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.

A Phase 2 interventional study of bevacizumab [Avastin] and 5 FU in Neoplasms, sponsored by Hoffmann-La Roche. Completed at 27 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-01-22.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
83
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This 2 arm study will assess the efficacy and safety of two systemic treatments including Avastin in patients with previously-untreated progressive locally advanced/metastatic well-differentiated digestive endocrine tumors. Patients with duodeno-pancreatic tumors (arm 1) will be treated with 5FU/streptozotocin iv (5FU 400mg/m2/d D1 to D5;streptozotocin 500mg/m2/d/iv D1 to D5;D1=D42) every 6 weeks, plus Avastin 7.5mg/kg iv every 3 weeks. Patients with gastrointestinal tract tumors (arm 2) will be treated with Xeloda 1000mg/m2 po bid D1 to D14 plus Avastin 7.5mg/kg iv D1=D21 every 3 weeks. The patients will be treated with chemotherapy for a minimum of 6 months, unless there is tumor progression and/or unacceptable toxicity. The anticipated time on study treatment is until disease progression or unacceptable toxicity, and the target sample size is \<100 individuals.

02

Conditions studied

  • Neoplasms

Browse trials for

03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 83 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.

Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients, >=18 years of age;
  • well-differentiated gastrointestinal tract endocrine tumors, or duodeno-pancreatic endocrine tumors;
  • no previous anti-cancer therapy, other than surgery;
  • progressive disease;
  • >=1 .

Exclusion criteria

Exclusion Criteria:

  • abnormal cardiac function, with history of ischemic heart disease in past 6 months and/or abnormal 12 lead ;
  • patients with known bleeding disorders;
  • unstable systemic disease;
  • chronic daily treatment with high-dose aspirin, NSAIDs or ;
  • previous history of (other than successfully treated basal and squamous cell cancer of the skin, and/or in situ cancer of the cervix).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
83 participants (actual)

Study arms

  • Experimental
    1

    Drug: bevacizumab [Avastin] · Drug: 5 FU · Drug: Streptozotocin

  • Experimental
    2

    Drug: bevacizumab [Avastin] · Drug: Xeloda

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) - Percentage of Participants With an Event

    PFS is defined as the interval between the date of start of treatment and the date of evaluation by the investigator of progressive disease or death from any cause. The progression was assessed according to Response Evaluation Criteria In Solid Tumors (RECIST) using medical imaging during the treatment period and by the investigators (confirmed by medical imaging) during the follow-up period. Data for participants who were lost to follow-up were censored at the date of last evaluation without progression. Data for participants who completed the study without an event of disease progression or death were censored at the date of the last visit or follow-up without progression.

    Time frame: Screening, every 3 months during treatment, every 6 months during follow-up to 2 years

  2. PFS - Time to Event

    PFS is defined as the interval between the date of start of treatment and the date of evaluation by the investigator of progressive disease or death from any cause. The progression was assessed according to RECIST using medical imaging during the treatment period and by the investigators (confirmed by medical imaging) during the follow-up period. Data for participants who were lost to follow-up were censored at the date of last evaluation without progression. Data for participants who completed the study without an event of disease progression or death were censored at the date of the last visit or follow-up without progression. Median PFS was estimated using the Kaplan-Meier method.

    Time frame: Screening, every 3 months during treatment, every 6 months during follow-up to 2 years

  3. PFS - Percentage of Participants Estimated to be Progression Free at 12 and 24 Months

    PFS is defined as the interval between the date of start of treatment and the date of evaluation by the investigator of progressive disease or death from any cause. The progression was assessed according to RECIST using medical imaging during the treatment period and by the investigators (confirmed by medical imaging) during the follow-up period. Data for participants who were lost to follow-up were censored at the date of last evaluation without progression. Data for participants who completed the study without an event of disease progression or death were censored at the date of the last visit or follow-up without progression.

    Time frame: Screening, every 3 months during treatment, every 6 months during follow-up to 2 years

Secondary outcomes

  1. Percentage of Participants With a Response by Best Overall Response

    Best overall response defined as best response recorded during the study as defined according to RECIST; performed by the investigator and by centralized review. Complete response (CR): complete disappearance of all target lesions and non-target disease. All lesions, both target and non-target, must have decreased to normal (short axis, less than \[\<\]10 millimeters \[mm\]). No new lesions. Partial response (PR): greater than or equal to (≥)30 percent (%) decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter (LD) was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. Stable disease (SD): not qualifying for CR, PR, or Progressive Disease (PD). PD: at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of 1 or more new lesions.

    Time frame: Screening, every 3 months during treatment, every 6 months during follow-up to 2 years

  2. Duration of Overall Response (OR) - Percentage of Participants With an Event

    Determined only for those participants with an overall response (CR or PR) and was defined as the time interval between the response (CR or PR) and the date of progression or death from any cause. Data for participants who were lost to follow-up were censored at the date of last evaluation without progression. Data for participants who completed the study without an event of progression or death were censored at the data of last visit or follow-up without progression.

    Time frame: Screening, every 3 months during treatment, every 6 months during follow-up to 2 years

  3. Duration of OR - Time to Event

    Determined only for those participants with an overall response (CR or PR) and was defined as the time interval between the response (CR or PR) and the date of progression or death from any cause. Data for participants who were lost to follow-up were censored at the date of last evaluation without progression. Data for participants who completed the study without an event of progression or death were censored at the data of last visit or follow-up without progression. Median duration of OR was estimated using the Kaplan-Meier method.

    Time frame: Screening, every 3 months during treatment, every 6 months during follow-up to 2 years

  4. Duration of OR - Percentage of Participants With Sustained Response at 12 and 24 Months

    Duration of OR was determined only for those participants with an overall response of CR or PR and was defined as the time interval between the response (CR or PR) and the date of progression or death from any cause. Data for participants who were lost to follow-up were censored at the date of last evaluation without progression. Data for participants who completed the study without an event of progression or death were censored at the data of last visit or follow-up without progression.

    Time frame: Screening, every 3 months during treatment, every 6 months during follow-up to 2 years

  5. Duration of Overall Disease Control (ODC) - Percentage of Participants With an Event

    Determined only for those participants with overall disease control (CR, PR or SD per RECIST) and was defined as the time interval between the first occurrence of disease control (CR, PR or SD) and the date of progression or death from any cause. Data for participants who were lost to follow-up were censored at the date of last evaluation without progression. Data for participants who completed the study without an event of progression or death were censored at the data of last visit or follow-up without progression.

    Time frame: Screening, every 3 months during treatment, every 6 months during follow-up to 2 years

  6. Duration of ODC - Time to Event

    Determined only for those participants with overall control disease (CR, PR, or SD per RECIST) and was defined as the time interval between the first occurrence of disease control (CR, PR or SD) and the date of progression or death from any cause. Data for participants who were lost to follow-up were censored at the date of last evaluation without progression. Data for participants who completed the study without an event of progression or death were censored at the data of last visit or follow-up without progression. Median time to event was estimated using the Kaplan-Meier method.

    Time frame: Screening, every 3 months during treatment, every 6 months during follow-up to 2 years

  7. Duration of ODC - Percentage of Participants Maintaining Disease Control at 12 and 24 Months

    Duration of ODC was determined only for those participants with overall control disease (CR, PR, or SD per RECIST) and was defined as the time interval between the first occurrence of disease control (CR, PR, or SD) and the date of progression or death from any cause. Data for participants who were lost to follow-up were censored at the date of last evaluation without progression. Data for participants who completed the study without an event of progression or death were censored at the data of last visit or follow-up without progression.

    Time frame: Screening, every 3 months during treatment, every 6 months during follow-up to 2 years

  8. Overall Survival (OS) - Percentage of Participants With an Event

    OS was defined as the time from the first treatment administration to death from any cause. Data for participants who were lost to follow-up were censored at the date of last evaluation. Data for participants who were alive at the end of the study were censored at the date of last visit.

    Time frame: Screening, Day 1 of every cycle during treatment, every 6 months during follow-up to 2 years

  9. OS - Time to Event

    OS was defined as the time from the first treatment administration to death from any cause. Data for participants who were lost to follow-up were censored at the date of last evaluation. Data for participants who were alive at the end of the study were censored at the date of last visit. Median OS was estimated using the Kaplan-Meier method.

    Time frame: Screening, Day 1 of every cycle during treatment, every 6 months during follow-up to 2 years

  10. OS - Percentage of Participants Surviving at 12 and 24 Months

    OS was defined as the time from the first treatment administration to death from any cause. Data for participants who were lost to follow-up were censored at the date of last evaluation. Data for participants who were alive at the end of the study were censored at the date of last visit.

    Time frame: Screening, Day 1 of every cycle during treatment, every 6 months during follow-up to 2 years

  11. Global Health Status as Assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - C30 (EORTC QLQ-C30)

    EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4-point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale \[1 'very poor' to 7 'Excellent'\]). Scores were averaged and transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms.

    Time frame: Screening, every 3 months during treatment

  12. Percentage of Participants With Change From Baseline in Global Health Status by EORTC QLQ-C30 Improvement Category

    EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4-point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale \[1 'very poor' to 7 'Excellent'\]). Scores averaged, transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms. Changes from baseline were categorized as follows: Very much worsening (less than \[\<\]-20); Moderate worsening (greater than or equal to \[≥\]-20 to \<-10); Little worsening (≥-10 to \<-5); No change (≥-5 to less than or equal to \[≤\]5); Little improvement (\>5 to ≤10); Moderate improvement (\>10 to ≤20); and Very much improved (\>20).

    Time frame: Screening, every 3 months during treatment

  13. EORTC QLQ-C30 Functional and Symptom Scale Scores

    EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4-point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale \[1 'very poor' to 7 'Excellent'\]). Scores averaged, transformed to 0-100 scale; for functional scores, a higher score represents a better level of functioning. For symptom scale scores a higher level represents a more severe level of symptoms.

    Time frame: Screening, every 3 months during treatment

07

Results

Posted Jan 22, 2015

Participant flow

Participant flow — Overall Study
MilestoneBevacizumab + 5-fluorouracil (5-FU) + StreptozocinBevacizumab + Capecitabine
Started3449
Completed3041
Not completed48
Withdrew: Death38
Withdrew: Investigator's decision (progression)10

Outcome measures

PrimaryProgression-Free Survival (PFS) - Percentage of Participants With an Event

PFS is defined as the interval between the date of start of treatment and the date of evaluation by the investigator of progressive disease or death from any cause. The progression was assessed according to Response Evaluation Criteria In Solid Tumors (RECIST) using medical imaging during the treatment period and by the investigators (confirmed by medical imaging) during the follow-up period. Data for participants who were lost to follow-up were censored at the date of last evaluation without progression. Data for participants who completed the study without an event of disease progression or death were censored at the date of the last visit or follow-up without progression.

Time frame:
Screening, every 3 months during treatment, every 6 months during follow-up to 2 years
Reported as:
Number · percentage of participants
Progression-Free Survival (PFS) - Percentage of Participants With an Event
percentage of participantsBevacizumab + 5-FU + StreptozocinBevacizumab + Capecitabine
Progression-Free Survival (PFS) - Percentage of Participants With an Event52.953.1
SecondaryPercentage of Participants With a Response by Best Overall Response

Best overall response defined as best response recorded during the study as defined according to RECIST; performed by the investigator and by centralized review. Complete response (CR): complete disappearance of all target lesions and non-target disease. All lesions, both target and non-target, must have decreased to normal (short axis, less than \[\<\]10 millimeters \[mm\]). No new lesions. Partial response (PR): greater than or equal to (≥)30 percent (%) decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter (LD) was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. Stable disease (SD): not qualifying for CR, PR, or Progressive Disease (PD). PD: at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of 1 or more new lesions.

Time frame:
Screening, every 3 months during treatment, every 6 months during follow-up to 2 years
Reported as:
Number · percentage of participants
Percentage of Participants With a Response by Best Overall Response
percentage of participantsBevacizumab + 5-FU + StreptozocinBevacizumab + Capecitabine
PR (Investigator)55.9 (39.2 to 72.6)18.4 (7.5 to 29.2)
PR (Centralized review)51.5 (34.5 to 68.6)12.5 (3.1 to 21.9)
SD (Investigator)44.1 (27.4 to 60.8)69.4 (56.5 to 82.3)
SD (Centralized review)48.5 (31.4 to 65.5)81.3 (70.2 to 92.3)
PD (Investigator)0 (0 to 0)8.2 (0.5 to 15.8)
PD (Centralized review)0 (0 to 0)0 (0 to 0)
Not evaluable (Investigator)0 (0 to 0)4.1 (0.0 to 9.6)
Not evaluable (Centralized review)0 (0 to 0)6.3 (0.0 to 13.1)
SecondaryDuration of Overall Response (OR) - Percentage of Participants With an Event

Determined only for those participants with an overall response (CR or PR) and was defined as the time interval between the response (CR or PR) and the date of progression or death from any cause. Data for participants who were lost to follow-up were censored at the date of last evaluation without progression. Data for participants who completed the study without an event of progression or death were censored at the data of last visit or follow-up without progression.

Time frame:
Screening, every 3 months during treatment, every 6 months during follow-up to 2 years
Reported as:
Number · percentage of participants
Duration of Overall Response (OR) - Percentage of Participants With an Event
percentage of participantsBevacizumab + 5-FU + StreptozocinBevacizumab + Capecitabine
Duration of Overall Response (OR) - Percentage of Participants With an Event42.122.2
PrimaryPFS - Time to Event

PFS is defined as the interval between the date of start of treatment and the date of evaluation by the investigator of progressive disease or death from any cause. The progression was assessed according to RECIST using medical imaging during the treatment period and by the investigators (confirmed by medical imaging) during the follow-up period. Data for participants who were lost to follow-up were censored at the date of last evaluation without progression. Data for participants who completed the study without an event of disease progression or death were censored at the date of the last visit or follow-up without progression. Median PFS was estimated using the Kaplan-Meier method.

Time frame:
Screening, every 3 months during treatment, every 6 months during follow-up to 2 years
Reported as:
Median · months
PFS - Time to Event
monthsBevacizumab + 5-FU + StreptozocinBevacizumab + Capecitabine
PFS - Time to Event23.7 (13.1 to NA)23.4 (13.2 to NA)
PrimaryPFS - Percentage of Participants Estimated to be Progression Free at 12 and 24 Months

PFS is defined as the interval between the date of start of treatment and the date of evaluation by the investigator of progressive disease or death from any cause. The progression was assessed according to RECIST using medical imaging during the treatment period and by the investigators (confirmed by medical imaging) during the follow-up period. Data for participants who were lost to follow-up were censored at the date of last evaluation without progression. Data for participants who completed the study without an event of disease progression or death were censored at the date of the last visit or follow-up without progression.

Time frame:
Screening, every 3 months during treatment, every 6 months during follow-up to 2 years
Reported as:
Number · percentage of participants
PFS - Percentage of Participants Estimated to be Progression Free at 12 and 24 Months
percentage of participantsBevacizumab + 5-FU + StreptozocinBevacizumab + Capecitabine
12 months7665
24 months5048
SecondaryDuration of OR - Time to Event

Determined only for those participants with an overall response (CR or PR) and was defined as the time interval between the response (CR or PR) and the date of progression or death from any cause. Data for participants who were lost to follow-up were censored at the date of last evaluation without progression. Data for participants who completed the study without an event of progression or death were censored at the data of last visit or follow-up without progression. Median duration of OR was estimated using the Kaplan-Meier method.

Time frame:
Screening, every 3 months during treatment, every 6 months during follow-up to 2 years
Reported as:
Median · months
Duration of OR - Time to Event
monthsBevacizumab + 5-FU + StreptozocinBevacizumab + Capecitabine
Duration of OR - Time to EventNA (11.2 to NA)NA (3.2 to NA)
SecondaryDuration of OR - Percentage of Participants With Sustained Response at 12 and 24 Months

Duration of OR was determined only for those participants with an overall response of CR or PR and was defined as the time interval between the response (CR or PR) and the date of progression or death from any cause. Data for participants who were lost to follow-up were censored at the date of last evaluation without progression. Data for participants who completed the study without an event of progression or death were censored at the data of last visit or follow-up without progression.

Time frame:
Screening, every 3 months during treatment, every 6 months during follow-up to 2 years
Reported as:
Number · percentage of participants
Duration of OR - Percentage of Participants With Sustained Response at 12 and 24 Months
percentage of participantsBevacizumab + 5-FU + StreptozocinBevacizumab + Capecitabine
12 months7470
24 months55NA
SecondaryDuration of Overall Disease Control (ODC) - Percentage of Participants With an Event

Determined only for those participants with overall disease control (CR, PR or SD per RECIST) and was defined as the time interval between the first occurrence of disease control (CR, PR or SD) and the date of progression or death from any cause. Data for participants who were lost to follow-up were censored at the date of last evaluation without progression. Data for participants who completed the study without an event of progression or death were censored at the data of last visit or follow-up without progression.

Time frame:
Screening, every 3 months during treatment, every 6 months during follow-up to 2 years
Reported as:
Number · percentage of participants
Duration of Overall Disease Control (ODC) - Percentage of Participants With an Event
percentage of participantsBevacizumab + 5-FU + StreptozocinBevacizumab + Capecitabine
Duration of Overall Disease Control (ODC) - Percentage of Participants With an Event52.946.5
SecondaryDuration of ODC - Time to Event

Determined only for those participants with overall control disease (CR, PR, or SD per RECIST) and was defined as the time interval between the first occurrence of disease control (CR, PR or SD) and the date of progression or death from any cause. Data for participants who were lost to follow-up were censored at the date of last evaluation without progression. Data for participants who completed the study without an event of progression or death were censored at the data of last visit or follow-up without progression. Median time to event was estimated using the Kaplan-Meier method.

Time frame:
Screening, every 3 months during treatment, every 6 months during follow-up to 2 years
Reported as:
Median · months
Duration of ODC - Time to Event
monthsBevacizumab + 5-FU + StreptozocinBevacizumab + Capecitabine
Duration of ODC - Time to Event22.3 (11.9 to NA)23.4 (15.1 to NA)
SecondaryDuration of ODC - Percentage of Participants Maintaining Disease Control at 12 and 24 Months

Duration of ODC was determined only for those participants with overall control disease (CR, PR, or SD per RECIST) and was defined as the time interval between the first occurrence of disease control (CR, PR, or SD) and the date of progression or death from any cause. Data for participants who were lost to follow-up were censored at the date of last evaluation without progression. Data for participants who completed the study without an event of progression or death were censored at the data of last visit or follow-up without progression.

Time frame:
Screening, every 3 months during treatment, every 6 months during follow-up to 2 years
Reported as:
Number · percentage of participants
Duration of ODC - Percentage of Participants Maintaining Disease Control at 12 and 24 Months
percentage of participantsBevacizumab + 5-FU + StreptozocinBevacizumab + Capecitabine
12 months6872
24 months42NA
SecondaryOverall Survival (OS) - Percentage of Participants With an Event

OS was defined as the time from the first treatment administration to death from any cause. Data for participants who were lost to follow-up were censored at the date of last evaluation. Data for participants who were alive at the end of the study were censored at the date of last visit.

Time frame:
Screening, Day 1 of every cycle during treatment, every 6 months during follow-up to 2 years
Reported as:
Number · percentage of participants
Overall Survival (OS) - Percentage of Participants With an Event
percentage of participantsBevacizumab + 5-FU + StreptozocinBevacizumab + Capecitabine
Overall Survival (OS) - Percentage of Participants With an Event14.716.3
SecondaryOS - Time to Event

OS was defined as the time from the first treatment administration to death from any cause. Data for participants who were lost to follow-up were censored at the date of last evaluation. Data for participants who were alive at the end of the study were censored at the date of last visit. Median OS was estimated using the Kaplan-Meier method.

Time frame:
Screening, Day 1 of every cycle during treatment, every 6 months during follow-up to 2 years
Reported as:
Median · months
OS - Time to Event
monthsBevacizumab + 5-FU + StreptozocinBevacizumab + Capecitabine
OS - Time to EventNA (27 to NA)NA (NA to NA)
SecondaryOS - Percentage of Participants Surviving at 12 and 24 Months

OS was defined as the time from the first treatment administration to death from any cause. Data for participants who were lost to follow-up were censored at the date of last evaluation. Data for participants who were alive at the end of the study were censored at the date of last visit.

Time frame:
Screening, Day 1 of every cycle during treatment, every 6 months during follow-up to 2 years
Reported as:
Number · percentage of participants
OS - Percentage of Participants Surviving at 12 and 24 Months
percentage of participantsBevacizumab + 5-FU + StreptozocinBevacizumab + Capecitabine
12 months9488
24 months8885
SecondaryGlobal Health Status as Assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - C30 (EORTC QLQ-C30)

EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4-point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale \[1 'very poor' to 7 'Excellent'\]). Scores were averaged and transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms.

Time frame:
Screening, every 3 months during treatment
Reported as:
Mean · units on a scale
Global Health Status as Assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - C30 (EORTC QLQ-C30)
units on a scaleBevacizumab + 5-FU + StreptozocinBevacizumab + Capecitabine
Baseline (n=29,40)65.23 ± 23.8965.42 ± 20.02
3 months (n=20,32)65.83 ± 19.4857.03 ± 22.41
6 months (n=20,24)60.00 ± 21.9066.32 ± 21.35
12 months (n=13,14)66.03 ± 17.8372.62 ± 19.46
End of treatment (n=13,23)64.74 ± 23.3657.97 ± 28.48
SecondaryPercentage of Participants With Change From Baseline in Global Health Status by EORTC QLQ-C30 Improvement Category

EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4-point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale \[1 'very poor' to 7 'Excellent'\]). Scores averaged, transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms. Changes from baseline were categorized as follows: Very much worsening (less than \[\<\]-20); Moderate worsening (greater than or equal to \[≥\]-20 to \<-10); Little worsening (≥-10 to \<-5); No change (≥-5 to less than or equal to \[≤\]5); Little improvement (\>5 to ≤10); Moderate improvement (\>10 to ≤20); and Very much improved (\>20).

Time frame:
Screening, every 3 months during treatment
Reported as:
Number · percentage of participants
Percentage of Participants With Change From Baseline in Global Health Status by EORTC QLQ-C30 Improvement Category
percentage of participantsBevacizumab + 5-FU + StreptozocinBevacizumab + Capecitabine
3 months, Very much worsening (n=20,29)10.017.2
3 months, Moderate worsening (n=20,29)10.024.1
3 months, Little worsening (n=20,29)10.017.2
3 months, No change (n=20,29)40.024.1
3 months, Little improving (n=20,29)5.03.4
3 months, Moderate Improving (n=20,29)15.03.4
3 months, Very much improving (n=20,29)10.010.3
6 months, Very much worsening (n=20,22)15.022.7
6 months, Moderate worsening (n=20,22)10.018.2
6 months, Little worsening (n=20,22)5.00
6 months, No change (n=20,22)35.031.8
6 months, Little improving (n=20,22)10.013.6
6 months, Moderate Improving (n=20,22)15.00
6 months, Very much improving (n=20,22)10.013.6
12 months, Very much worsening (n=12,13)8.30
12 months, Moderate worsening (n=12,13)8.315.4
12 months - Little worsening (n=12,13)33.315.4
12 months, No change (n=12,13)25.038.5
12 months, Little improving (n=12,13)8.37.7
12 months, Moderate Improving (n=12,13)16.715.4
12 months, Very much improving (n=12,13)07.7
End of treatment, Very much worsening (n=13,20)15.415.0
End of treatment, Moderate worsening (n=13,20)30.85.0
End of treatment, Little worsening (n=13,20)010.0
End of treatment, No change (n=13,20)15.445.0
End of treatment, Little improving (n=13,20)15.410.0
End of treatment, Moderate Improving (n=13,20)15.45.0
End of treatment, Very much improving (n=13,20)7.710.0
SecondaryEORTC QLQ-C30 Functional and Symptom Scale Scores

EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4-point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale \[1 'very poor' to 7 'Excellent'\]). Scores averaged, transformed to 0-100 scale; for functional scores, a higher score represents a better level of functioning. For symptom scale scores a higher level represents a more severe level of symptoms.

Time frame:
Screening, every 3 months during treatment
Reported as:
Mean · units on a scale
EORTC QLQ-C30 Functional and Symptom Scale Scores
units on a scaleBevacizumab + 5-FU + StreptozocinBevacizumab + Capecitabine
Physical functioning, Baseline (n=30,43)90.44 ± 13.3087.71 ± 14.88
Physical functioning, 3 months (n=22,33)89.32 ± 12.7775.35 ± 24.07
Physical functioning, 6 months (n=21,24)81.98 ± 19.7582.50 ± 18.21
Physical functioning, End of Treatment (n=13,24)82.82 ± 20.2179.44 ± 19.85
Role functioning, Baseline (n=30,43)82.22 ± 27.3183.33 ± 25.46
Role functioning, 3 months (n=22,33)85.61 ± 21.3962.12 ± 33.66
Role functioning, 6 months (n=21,24)75.40 ± 29.1670.83 ± 28.34
Role functioning, End of Treatment (n=13,24)78.21 ± 32.9072.92 ± 29.00
Emotional functioning, Baseline (n=30,42)71.94 ± 28.3271.89 ± 20.50
Emotional functioning, 3 months (n=21,33)81.48 ± 20.5376.01 ± 24.27
Emotional functioning, 6 months (n=21,24)72.62 ± 28.2876.04 ± 26.27
Emotional functioning, End of Treatment (n=13,24)77.56 ± 23.1773.61 ± 24.04
Cognitive functioning, Baseline (n=30,42)86.67 ± 18.2687.30 ± 16.38
Cognitive functioning, 3 months (n=22,33)89.39 ± 15.0483.84 ± 21.03
Cognitive functioning, 6 months (n=21,24)83.33 ± 21.0882.64 ± 18.04
Cognitive functioning, End of Treatment (n=13,24)83.33 ± 22.5781.94 ± 25.97
Social functioning, Baseline (n=30,41)86.11 ± 21.4887.40 ± 20.34
Social functioning, 3 months (n=22,33)89.39 ± 17.4875.76 ± 27.35
Social functioning, 6 months (n=21,24)81.75 ± 26.3083.33 ± 21.42
Social functioning, End of Treatment (n=13,24)84.62 ± 24.9681.94 ± 21.93
Fatigue, Baseline (n=30,42)26.30 ± 23.6127.25 ± 21.70
Fatigue, 3 months (n=21,33)27.78 ± 23.7043.10 ± 31.76
Fatigue, 6 months (n=20,24)36.67 ± 29.0937.96 ± 23.61
Fatigue, End of Treatment (n=13,24)34.19 ± 28.8534.49 ± 32.93
Nausea and vomiting, Baseline (n=30,42)6.67 ± 14.912.78 ± 7.29
Nausea and vomiting, 3 months (n=22,33)10.61 ± 14.139.60 ± 16.15
Nausea and vomiting, 6 months (n=21,24)8.73 ± 17.977.64 ± 12.98
Nausea and vomiting, End of Treatment (n=13,24)10.26 ± 19.886.25 ± 14.59
Pain, Baseline (n=30,43)14.44 ± 19.4421.71 ± 27.83
Pain, 3 months (n=22,33)12.88 ± 18.5018.18 ± 25.47
Pain, 6 months (n=21,24)23.02 ± 31.8317.36 ± 19.95
Pain, End of Treatment (n=13,24)20.51 ± 28.1826.39 ± 32.94
Dyspnea, Baseline (n=30,43)16.67 ± 25.8916.28 ± 25.59
Dyspnea, 3 months (n=21,33)12.70 ± 19.6530.30 ± 32.66
Dyspnea, 6 months (n=21,23)19.05 ± 24.8823.19 ± 29.19
Dyspnea, End of Treatment (n=13,24)20.51 ± 28.9923.61 ± 30.26
Insomnia, Baseline (n=30,43)24.44 ± 27.5924.03 ± 24.48
Insomnia, 3 months (n=21,33)20.63 ± 22.3027.27 ± 30.57
Insomnia, 6 months (n=21,24)33.33 ± 34.9629.17 ± 30.00
Insomnia, End of Treatment (n=13,24)23.08 ± 25.0430.56 ± 33.93
Appetite loss, Baseline (n=29,42)12.64 ± 16.468.73 ± 20.90
Appetite loss, 3 months (n=22,33)7.58 ± 14.3020.20 ± 24.92
Appetite loss, 6 months (n=21,24)15.87 ± 27.1225.00 ± 26.47
Appetite loss, End of Treatment (n=13,24)12.82 ± 28.9925.00 ± 32.97
Constipation, Baseline (n=27,40)4.94 ± 15.2010.00 ± 21.62
Constipation, 3 months (n=21,33)15.87 ± 27.127.07 ± 18.18
Constipation, 6 months (n=21,23)17.46 ± 27.1211.59 ± 21.58
Constipation, End of Treatment (n=13,24)12.82 ± 21.6813.89 ± 25.85
Diarrhea, Baseline (n=30,41)13.33 ± 24.1337.40 ± 31.79
Diarrhea, 3 months (n=22,32)9.09 ± 21.0445.83 ± 34.65
Diarrhea, 6 months (n=21,23)6.35 ± 17.0643.48 ± 30.87
Diarrhea, End of Treatment (n=12,22)2.78 ± 9.6228.79 ± 31.36
Financial difficulties, Baseline (n=30,413)14.44 ± 25.808.13 ± 17.92
Financial difficulties, 3 months (n=22,33)9.09 ± 15.196.06 ± 15.49
Financial difficulties, 6 months (n=21,23)15.87 ± 24.992.90 ± 9.60
Financial difficulties, End of treatment (n=13,24)17.95 ± 25.884.17 ± 14.95

Adverse events

Collected over Adverse events (AEs) were collected from the date of first dose of study medication until 28 days after the last dose of study medication. Related serious AEs and AEs of special interest (AESIs) were recorded during follow-up.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bevacizumab + 5-FU + Streptozocin—11/34 (32.4%)34/34 (100%)
Bevacizumab + Capecitabine—13/49 (26.5%)49/49 (100%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventBevacizumab + 5-FU + StreptozocinBevacizumab + Capecitabine
PyrexiaGeneral disorders3/340/49
Abdominal pain upperGastrointestinal disorders2/340/49
Gastrointestinal hemorrhageGastrointestinal disorders2/340/49
HypoglycaemiaMetabolism and nutrition disorders2/340/49
Abdominal painGastrointestinal disorders0/342/49
Intestinal obstructionGastrointestinal disorders0/342/49
General physical health deteriorationGeneral disorders0/342/49
Influenza like illnessGeneral disorders1/340/49
Post-procedural sepsisInfections and infestations1/340/49
Pleural effusionRespiratory, thoracic and mediastinal disorders1/340/49
Most frequent other events
Showing 10 of 266
Most frequent other events
EventBevacizumab + 5-FU + StreptozocinBevacizumab + Capecitabine
NauseaGastrointestinal disorders24/3424/49
AstheniaGeneral disorders23/3428/49
DiarrhoeaGastrointestinal disorders12/3432/49
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders6/3431/49
ConstipationGastrointestinal disorders19/349/49
Mucosal inflammationGeneral disorders14/3417/49
Abdominal painGastrointestinal disorders13/3412/49
HeadacheNervous system disorders13/3414/49
Abdominal pain upperGastrointestinal disorders11/3411/49
VomitingGastrointestinal disorders11/347/49

Baseline characteristics

Intent-to-treat (ITT) population: all participants who received at least 1 dose of treatment.

Age, Continuous
Age, Continuous(years)Bevacizumab + 5-FU + StreptozocinBevacizumab + CapecitabineTotal
Mean55.93 ± 10.6361.64 ± 9.2059.29 ± 10.15
Sex: Female, Male
Sex: Female, Male(Participants)Bevacizumab + 5-FU + StreptozocinBevacizumab + CapecitabineTotal
Female122335
Male222648
08

Study locations

27 sites
  • Angers, 49933, France
  • Bordeaux, 33075, France
  • Boulogne Billancourt, 92104, France
  • Caen, 14033, France
  • Chambray Les Tours, 37171, France
  • Clichy, 92118, France
  • Creteil, 94010, France
  • Dijon, 21079, France
  • Lille, 59020, France
  • Lyon, 69437, France
  • Marseille, 13273, France
  • Marseille, 13285, France
  • Marseille, 13385, France
  • Montpellier, 34298, France
  • Nantes, 44093, France
  • Nice, 06189, France
  • Paris, 75571, France
  • Paris, 75651, France
  • Paris, 75908, France
  • Paris, 75970, France
  • Poitiers, 86021, France
  • Reims, 51092, France
  • Rouen, 76031, France
  • Saint Brieuc, 22015, France
  • Strasbourg, 67091, France
  • Toulouse, 31059, France
  • Villejuif, 94805, France
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2007, a primary completion of Nov 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2015, 3 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2007
First posted
Mar 16, 2007
Start
Jul 2007
Primary completionActual
Nov 2011
CompletionActual
Nov 2011
Results first posted
Jan 22, 2015
Last update
Jan 22, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00448136
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Mar 16, 2007
Start date
Jul 2007
Primary completion
Nov 2011
Completion
Nov 2011
Results posted
Jan 22, 2015
Last update
Jan 22, 2015

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluorouracil · Streptozocin · Capecitabine

Start the discussion